Last reviewed · How we verify
NCT05856084
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Phase 2 trial testing Low dose Recombinant Herpes Zoster Vaccine (CHO cells) in Herpes Zoster in 924 participants. Participants enrolled and being followed up; not accepting new ones.
28 December 2024
Quick facts
| Lead sponsor | MAXVAX Biotechnology Limited Liability Company |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 924 |
| Start date | 7 May 2023 |
| Primary completion | 28 December 2024 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Low dose Recombinant Herpes Zoster Vaccine (CHO cells) — full drug profile →
- High dose Recombinant Herpes Zoster Vaccine (CHO cells) — full drug profile →
- Positive control — full drug profile →
- Placebo
Conditions studied
- Herpes Zoster — all drugs for Herpes Zoster →
Sponsor
MAXVAX Biotechnology Limited Liability Company — full company profile →
Who can join
30 and older, any sex, with Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05856084
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Herpes Zoster
Currently open trials in the same condition.
- NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
- NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
- NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting
Other MAXVAX Biotechnology Limited Liability Company trials
Trials by the same sponsor.
- NCT07492706 — Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adul · Phase 1 · not yet recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT07272434 — Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) · Phase 3 · recruiting
- NCT06654700 — Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). · Phase 3 · not yet recruiting
- NCT06642558 — Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05856084 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MAXVAX Biotechnology Limited Liability Company
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05856084.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing